Cara Therapeutics Inc
Cara Therapeutics Inc is listed today as Tvardi Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2010 | $5 M | No. 1 | $2 to $10 million | equity, options | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Cara Therapeutics Inc chose not to state its revenue in its newest notice of a funding round (Jul 2010).
SEC Form D · Jul 2010
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2010
Products and services#
No products or services of Cara Therapeutics Inc are on record.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alta Biopharma Management III LLC | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Alta Biopharma Partners III Gmbh & Co Beteiligungs KG | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Alta Biopharma Partners III LP | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Alta Embarcadero Biopharma Partners III LLC | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Derek T. Chalmers | Person | not stated | not stated | Held Series A and D preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Michael E. Lewis | Person | not stated | not stated | Held Series A and D preferred stock (Form 3, 2014) | SEC Form 3 |
| Rho Capital Partners LLC | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| RHO Ventures VI LP | Venture capital | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| RMV VI, L.L.C. | Other | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Largest shareholders today
Institutions holding Tvardi Therapeutics, Inc. shares, as of Sep 30, 2026.
- Slate Path Capital LP$1 M5.28%
- Vanguard Capital Management LLC$0 M2.58%
- Raymond James Financial Inc$0 M2.09%
- Two Sigma Investments, LP$0 M1.81%
- American Financial Group Inc$0 M1.68%
- Jpmorgan Chase & Co$0 M1.52%
- Captrust Financial Advisors$0 M1.50%
- Renaissance Technologies LLC$0 M1.01%
- Bank Of America Corp /de/$0 M0.99%
- Geode Capital Management, LLC$0 M0.90%
- Silvercrest Asset Management Group LLC$0 M0.76%
- BlackRock, Inc.$0 M0.71%
- Verition Fund Management LLC$0 M0.65%
- Bridgeway Capital Management, LLC$0 M0.60%
- Morgan Stanley$0 M0.59%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Derek Chalmers | Executive officer | Jul 2010 |
| Frederique Menzaghi | Executive officer | Jul 2010 |
| Josef Schoell | Executive officer | Jul 2010 |
| Christopher M. Moller | Director | Jul 2010 |
| Dean Slagel | Director | Jul 2010 |
| Derek Chalmers | Director | Jul 2010 |
| Ed Hurwitz | Director | Jul 2010 |
| Jeffrey M. Jonas | Director | Jul 2010 |
| Martin Vogelbaum | Director | Jul 2010 |
| Stephen Reeders | Director | Jul 2010 |
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.